In developed countries, up to 20% of the population suffers from pollen allergies to birch and related trees. Mabylon AG has developed an anti-tree pollen antibody therapeutic, MY-010, that targets several inducers of spring hay fever, such as birch, alder and hazel, among others.

Mabylon AG has raised a total of CHF30 million (US$37 million) to advance its pipeline and support its work using human-derived, multi-specific antibodies for the treatment of allergies. The funding combines equity investment and a convertible loan.

Mabylon AG recently provided preclinical data for MY-006, a half-life extended trispecific anti-peanut antibody being developed for the treatment of peanut allergy.

Mabylon AG has been awarded three grants totaling more than CHF1.3 million (US$1.5 million) from Innosuisse Swiss Innovation Agency, Target ALS and the ALS Association.